As the 1st to market generic Clarithromycin IV in South Africa, CLARICULE provides prescribers with a safe and effective option for treating upper and lower respiratory tract infections.
We are proud to announce the launch of CLARICULE 500 mg powder for solution for infusion, medium and broad spectrum, macrolide antibiotic. CLARICULE acts by selectively binding to the ribosomes of susceptible bacteria, preventing translocation of activated amino acids and inhibiting the intracellular protein synthesis of susceptible bacteria. CLARICULE is active against several bacterial strains including: H. influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Morazella (Brahamella) catarrhalis, Neisseria gonorrhoeae, Helicobacter pylori and Campylobacter spp.
This course contains the full professional information for CLARICULE as approved by the South African Health Products Regulatory Authority.
Pharmacists and prescribing Medical Practitioners
Professional Information for CLARICULE included in the course: